The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Co-mutation of ATM and ASXL1 and relationship to durable response of a novel PARP1/2 inhibitor, venadaparib, in patients with pancreatic cancer.
 
Keun Seok Lee
Consulting or Advisory Role - Bixink; Everest Pharmaceutical; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Dong-A ST
 
Woo Jin Lee
No Relationships to Disclose
 
Heejung Chae
No Relationships to Disclose
 
Keun-Wook Lee
Honoraria - Boryung; JW Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; Sanofi/Aventis; Vifor Pharma
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); GC Pharma (Inst); Genome & Company (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeiGene Beijing; BeyondBIO; Bristol-Myers Squibb/Celgene; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; TCUBEit
 
Hee Kyung Ahn
No Relationships to Disclose
 
Inkeun Park
No Relationships to Disclose
 
Jin Hyoung Kang
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genexine; MSD Oncology; Ono Pharmaceutical; Yuhan
Speakers' Bureau - Boehringer Ingelheim; Pfizer; Roche
Research Funding - AstraZeneca; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Yuhan
 
Se Jun Park
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Jeesun Yoon
No Relationships to Disclose
 
Won Sik Lee
Employment - Idience
Leadership - Idience
 
Chan-Young Ock
Employment - Lunit
Leadership - Lunit
Stock and Other Ownership Interests - Lunit; Medpacto; Y-Biologics
Consulting or Advisory Role - Genome & Company; Idience; Medpacto; PIN therapeutics; Selecxine; Y-Biologics
 
Aili Wang
Employment - Idience
 
Eunyoung Heo
Employment - Idience
 
Jeongsook Bang
Employment - Idience
 
Min Ju Hong
Employment - Idience
Stock and Other Ownership Interests - Idience
Travel, Accommodations, Expenses - Idience
 
Eun-Jihn Roh
Employment - Idience
Leadership - Idience
 
KYOUNG SOO HA
Employment - Idience
Leadership - Idience
Stock and Other Ownership Interests - SillaJen